Digital Respiratory Health Amiko's Respiro platform integrates data, AI, and connected inhalers to upgrade respiratory care, presenting a strong cross-sell opportunity with healthcare providers and payers seeking digital medicine solutions for asthma and COPD management.

Clinical Validation Recent RDD 2026 results show substantial improvement in inhalation technique among patients using Respiro, which can be leveraged in sales pitches to demonstrate value, adherence benefits, and potential reductions in adverse events.

Pharmacy Collaboration Partnership with Sanner Group indicates openness to sensor-enabled add-ons and integrated device solutions, suggesting a path to expand into device manufacturers, pharmacists, and pharmaceutical services for adherence tech.

Growing Market Presence With a revenue range in the hundreds of millions and a focus on digital health within wellness and fitness services, Amiko targets scale opportunities in enterprise health programs, health systems, and payer-led initiatives.

Competitive Positioning Amiko positions itself against competitors like Propeller Health, highlighting a differentiated approach in digital respiratory care that can be leveraged to win contracts where integrated data platforms and patient engagement are prioritized.